ImmuPharma plc (LON:IMM – Get Free Report)’s stock price dropped 14.4% during trading on Monday . The stock traded as low as GBX 8.33 ($0.11) and last traded at GBX 8.95 ($0.12). Approximately 12,629,833 shares traded hands during trading, an increase of 47% from the average daily volume of 8,586,172 shares. The stock had previously closed at GBX 10.45 ($0.14).
ImmuPharma Price Performance
The firm’s 50 day moving average is GBX 5.17 and its 200 day moving average is GBX 3.54. The company has a market cap of £44.73 million, a PE ratio of -1,005.62 and a beta of 1.53.
ImmuPharma (LON:IMM – Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- What to Know About Investing in Penny Stocks
- Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300
- Are Penny Stocks a Good Fit for Your Portfolio?
- Cathie Wood Buys Alibaba and Baidu: Momentum or More Value Ahead?
- 3 REITs to Buy and Hold for the Long Term
- This ETF Weeds Out Small-Cap Underperformers
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
